Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Durie

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2009
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204)Mohamad A Hussein, Vanessa Bolejack, Jeffrey A Zonder, et al.
Nature Reviews. Clinical Oncology|April 8, 2025
Opportunities and challenges for MRD assessment in the clinical management of multiple myelomaBruno Paiva, Qian Shi, Noemi Puig, et al.
Journal of Clinical Nursing|May 1, 1995
A critique of 'at risk' pressure sore assessment toolsL N Smith, N Booth, D Douglas, et al.
Blood Advances|January 4, 2018
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methodsMikhail Roshal, Juan A Flores-Montero, Qi Gao, et al.
Advances in Therapy|March 18, 2024
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level DataBrian G M Durie, Shaji K Kumar, Eric M Ammann, et al.
Blood Advances|August 28, 2023
Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myelomaBruno Paiva, Anastasiia Zherniakova, Jorge M Nuñez-Córdoba, et al.
The Lancet. Oncology|November 2, 2013
Management of multiple myeloma in Asia: resource-stratified guidelinesDaryl Tan, Wee Joo Chng, Takaaki Chou, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 25, 2015
Connect MM Registry: The Importance of Establishing Baseline Disease CharacteristicsRobert M Rifkin, Rafat Abonour, Howard Terebelo, et al.
British Journal of Haematology|June 15, 2005
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Wolf, et al.
Blood|September 30, 2010
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Jeffrey A Zonder, John Crowley, Mohamad A Hussein, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2009
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204)Mohamad A Hussein, Vanessa Bolejack, Jeffrey A Zonder, et al.
Nature Reviews. Clinical Oncology|April 8, 2025
Opportunities and challenges for MRD assessment in the clinical management of multiple myelomaBruno Paiva, Qian Shi, Noemi Puig, et al.
Journal of Clinical Nursing|May 1, 1995
A critique of 'at risk' pressure sore assessment toolsL N Smith, N Booth, D Douglas, et al.
Blood Advances|January 4, 2018
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methodsMikhail Roshal, Juan A Flores-Montero, Qi Gao, et al.
Advances in Therapy|March 18, 2024
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level DataBrian G M Durie, Shaji K Kumar, Eric M Ammann, et al.
Blood Advances|August 28, 2023
Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myelomaBruno Paiva, Anastasiia Zherniakova, Jorge M Nuñez-Córdoba, et al.
The Lancet. Oncology|November 2, 2013
Management of multiple myeloma in Asia: resource-stratified guidelinesDaryl Tan, Wee Joo Chng, Takaaki Chou, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 25, 2015
Connect MM Registry: The Importance of Establishing Baseline Disease CharacteristicsRobert M Rifkin, Rafat Abonour, Howard Terebelo, et al.
British Journal of Haematology|June 15, 2005
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Wolf, et al.
Blood|September 30, 2010
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Jeffrey A Zonder, John Crowley, Mohamad A Hussein, et al.
Pageof 15